Novabay Pharmaceuticals (NBY) Registration Filing summary

Company overview and business model

• Transitioning from eyecare and wound care products to a new strategic direction after divesting all operational product lines in early 2025.

• Exploring opportunities in emerging financial infrastructure and network-based markets, including select blockchain-based assets.

• Evaluating potential strategic transactions to enhance capital efficiency and long-term stockholder value.

Financial performance and metrics

• Revenue from continuing operations for the year ended December 31, 2024, was approximately $9.7 million, primarily from eyecare product sales before divestiture.

• Wound care product revenue decreased compared to 2023.

• As of November 24, 2025, the aggregate market value of outstanding common stock held by non-affiliates was approximately $5.9 million, with 126,010,749 shares outstanding.

Use of proceeds and capital allocation

• Net proceeds from securities sales are intended for working capital and general corporate purposes, including sales and marketing, R&D, and administrative expenses.